Novel fluoro-quinazoline derivatives bearing a bioreductive group for tumoral hypoxia diagnosis

• Grant number: 17/04599-5
• Support Opportunities: Scholarships abroad - Research Internship - Doctorate
• Start date: May 12, 2017
• End date: November 11, 2017
• Field of knowledge: Health Sciences - Pharmacy
• Principal Investigator: Ivone Carvalho
• Grantee: Paulo Sérgio Gonçalves Nunes
• Supervisor: Kuo-Shyan Lin
• Host Institution: Faculdade de Ciências Farmacêuticas de Ribeirão Preto (FCFRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil
• Institution abroad: University of British Columbia, Vancouver (UBC), Canada
• Associated to the scholarship: 13/27186-7 - Biorreductive Quinazolines: synthesis and biological evaluation for PET diagnostic and treatment of hypoxic tumors, BP.DR

Abstract

Tumor hypoxia diagnosis is extremely important for the accurate cancer treatment, since some type of somatic lesions have negative prognosis. Amongst the hypoxia diagnostic tools, molecular PET is the most sensitive method and non-invasive once it uses radiotracers bearing specific reactive groups that exploits differences between the reducing potential of a tumor microenvironment in normoxia and hypoxia. The present work aims to identify new molecular probes for hypoxia tumors diagnosis from a quinazoline core, which is a privileged structure in cancer treatment. The target quinazoline-based compounds (series A and B) comprise two different functional motifs, the bioreductive (2-nitroimidazole) and the radiotracer (radionuclide 18F), switching at C-4 and C-6 positions of the quinazoline ring. Regarding the radiotracer motif, classical fluor-ethylene and trifluoroborate groups along with Copper(I)-Catalyzed Azide-Alkyne Cycloaddition (CuAAC) reactions (Click Chemistry strategy) will enable the synthesis of a small set of potential probes. Moreover, we also have proposed the synthesis a derivative without the quinazoline scaffold in order to evaluate its biological impact/influence in the absence of the quinazoline core when compared to the quinazoline derivatives. The synthesized compounds will be then evaluated toward their stability in mouse plasma, PET/CT imaging and biodistribution, partition coefficients and in vitro cell uptake.

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

GONCALVES NUNES, PAULO SERGIO; ZHANG, ZHENGXING; KUO, HSIOU-TING; ZHANG, CHENGCHENG; ROUSSEAU, JULIE; ROUSSEAU, ETIENNE; LAU, JOSEPH; KWON, DANIEL; CARVALHO, IVONE; BENARD, FRANCOIS; et al. Synthesis and evaluation of an F-18-labeled trifluoroborate derivative of 2-nitroimidazole for imaging tumor hypoxia with positron emission tomography. JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, v. 61, n. 4, p. 370-379, APR 2018. (17/04599-5)